<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has submitted an annual disclosure confirming that it does not qualify as a 'Large Corporate' under SEBI regulations. The company states it does not meet the applicability criteria outlined in SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. As a result, Glenmark is not required to submit the detailed disclosures mandated for Large Corporates. This filing serves as a negative confirmation and was signed by Company Secretary Harish Kuber and Executive Director & CFO Anurag Mantri on April 30, 2026.
No direct impact on shareholders or stock price. This is a routine compliance filing confirming the company's current classification status under SEBI norms.